-transparent.png){kind=logo}
Twenty-two subjects 6-12 years old who met Research Diagnostic Criteria and DSM-III criteria for major depressive disorder received a fixed daily dose of nortriptyline during an 8-week protocol. Weekly plasma levels were measured; the raters performing behavioral assessments were blind to these levels. There was a highly significant difference between the mean steady-state plasma levels and the milligram-per-kilogram doses of the responders and nonresponders. The data suggest that the lower limit of the therapeutic range of nortriptyline in children (over 60 ng/ml) is similar to that reported for adults. The disadvantages of the use of a milligram-per-kilogram dose rather than a pharmacokinetic approach are discussed.
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
August 1971,
British medical journal,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
January 1976,
Pharmakopsychiatrie, Neuro-Psychopharmakologie,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
December 1977,
Pharmakopsychiatrie, Neuro-Psychopharmakologie,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
January 1982,
International pharmacopsychiatry,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
January 1972,
Pharmacology,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
May 1992,
Progress in neuro-psychopharmacology & biological psychiatry,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
October 1997,
The Journal of clinical psychiatry,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
January 1986,
Therapeutic drug monitoring,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
January 1982,
Psychopharmacology,
B Geller, and
T B Cooper, and
E C Chestnut, and
J A Anker, and
M D Schluchter
January 1987,
Acta psychiatrica Scandinavica,
